West Pharmaceutical Services (WST) cash flow statement
TrendArc score 67 of 100 · Health 7.6 · Momentum 8.8 · Moat 6.8 · scored Nov 17, 2026 · How the score works
Free cash flow, fiscal year to December 31, 2025
$469 million
up 69.6% from the year before
West Pharmaceutical Services generated $469 million of free cash flow in the fiscal year to December 2025: $755 million of cash from operations less $286 million of capital spending. That was 15.3% of revenue, against 9.6% the year before. Over the last four quarters, to September 30, 2026, it was $580 million.
What stands out
- Over the five fiscal years to December 2025 it paid $1.7 billion in dividends and net share repurchases, 87% of its free cash flow over the same years.
- Free cash flow was below net income in each of the last five fiscal years; in the fiscal year to December 2025 it was 95% of net income.
- Cash dividends paid rose in each of the last five fiscal years, from $48 million to $61 million in total.
Each sentence is written by a fixed rule from the figures on this page.
Free cash flow and net income, the last 10 fiscal years
Fiscal years, each labelled by the calendar year it ended in. Every figure is in the statement below.
Where the cash wentFiscal year to December 31, 2025
- Cash from operations 755
- Capital spending -286
- Free cash flow 469
- Net share repurchases -126
- Dividends -61
- Debt and other 25
- Net change in cash 307
In millions of US dollars. Outflows are grey, not red: a buyback is not a loss. "Debt and other" closes the gap to the reported change in cash. Buying marketable securities moves cash into short-term investments; the balance sheet shows both.
Cash flow statement, the last 10 fiscal years
| Fiscal year to | Last 4 quarters to Sep 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | |||||||||||
| Net income | 494 | 493 | 593 | 586 | 662 | 346 | 242 | 207 | 151 | 144 | |
| Depreciation and amortisation | 171 | 155 | 137 | 121 | 122 | 109 | 103 | 104 | 97 | 91 | |
| Stock-based pay | 29 | 24 | 19 | 23 | 24 | 38 | 34 | 24 | 15 | 16 | 20 |
| Working capital and other items | 66 | -13 | 23 | -6 | -238 | -17 | -2 | -38 | 0 | -34 | |
| Cash from operations | 655 | 755 | 653 | 777 | 724 | 584 | 473 | 367 | 289 | 263 | 219 |
| Investing activities | |||||||||||
| Capital spending | -74 | -286 | -377 | -362 | -285 | -253 | -174 | -126 | -105 | -131 | -170 |
| Businesses bought and sold, net | 0 | 0 | 0 | 0 | -2 | 0 | -104 | 0 | -6 | -8 | |
| Investments bought and sold, net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Cash from investing | -286 | -379 | -369 | -288 | -253 | -180 | -228 | -101 | -134 | -176 | |
| Financing activities | |||||||||||
| Debt issued or repaid, net | -1 | -28 | -2 | -46 | -2 | -2 | 61 | 0 | -35 | -70 | |
| Shares issued less bought back | -669 | -126 | -541 | -407 | -201 | -123 | -93 | -58 | -43 | -39 | -30 |
| Dividends paid | -63 | -61 | -59 | -57 | -54 | -51 | -48 | -45 | -42 | -39 | -36 |
| Other financing | 3 | 5 | 7 | 7 | 8 | 6 | 5 | 5 | 4 | 22 | |
| Cash from financing | -185 | -623 | -460 | -294 | -168 | -137 | -37 | -81 | -109 | -114 | |
| Exchange rate effect | 23 | -21 | 11 | -11 | -16 | 21 | -1 | -6 | 12 | -1 | |
| Net change in cash | 307 | -369 | -40 | 132 | 147 | 176 | 102 | 102 | 33 | -72 | |
| Free cash flow | |||||||||||
| Free cash flow | 580 | 469 | 276 | 415 | 439 | 331 | 298 | 241 | 184 | 133 | 49 |
| Free cash flow margin | 17.1% | 15.3% | 9.6% | 14.1% | 15.2% | 11.7% | 13.9% | 13.1% | 10.7% | 8.3% | 3.3% |
| Free cash flow per share | $6.45 | $3.75 | $5.50 | $5.80 | $4.33 | $3.93 | $3.19 | $2.44 | $1.75 | $0.66 | |
Shares issued less bought back is the cash from shares sold less the cash paid for shares bought back (negative when more was bought back), and includes tax withheld when employees' shares vest. Working capital and other items is cash from operations less net income, depreciation and amortisation, and stock-based pay (calculated by TrendArc). Company filings as standardised by Tiingo; calculations by TrendArc. Rebuilt nightly.
West Pharmaceutical Services against its peers
| Company | Fiscal year to | Free cash flow | Free cash flow margin |
|---|---|---|---|
| ResMedRMD | Jun 2026 | $1.65B | 29.2% |
| DexcomDXCM | Dec 2025 | $1.08B | 23.1% |
| IlluminaILMN | Dec 2025 | $931M | 21.4% |
| Mettler ToledoMTD | Dec 2025 | $849M | 21.1% |
| SterisSTE | Mar 2026 | $983M | 16.6% |
| West Pharmaceutical ServicesWST | Dec 2025 | $469M | 15.3% |
| IQVIAIQV | Dec 2025 | $2.13B | 13.0% |
| GE HealthCareGEHC | Dec 2025 | $1.50B | 7.3% |
| Peer median | 21.1% |
Each company's newest fiscal year; some end in other months. The peers are the stock card's peer group.
Next
Follow West Pharmaceutical Services with a free account.
A watchlist, price alerts and saved chart layouts. No card needed.
Sign up freeNo forecast, no recommendation. This page describes West Pharmaceutical Services from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Nov 17, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.
The TrendArc score, from 0 to 100, combines three pillars measured from published data, Health (business quality over the last twelve months), Momentum (the price against its moving averages, its 52-week high and the market) and Moat (durability over five years), with the share price's long-run trend. It describes the company as it stands today. It is not a forecast or a recommendation.